NASDAQ:MLTX MoonLake Immunotherapeutics Q1 2025 Earnings Report $18.71 -1.17 (-5.89%) Closing price 04:00 PM EasternExtended Trading$19.00 +0.29 (+1.52%) As of 05:03 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. ProfileEarnings HistoryForecast MoonLake Immunotherapeutics EPS ResultsActual EPS-$0.63Consensus EPS -$0.76Beat/MissBeat by +$0.13One Year Ago EPS-$0.22MoonLake Immunotherapeutics Revenue ResultsActual RevenueN/AExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/AMoonLake Immunotherapeutics Announcement DetailsQuarterQ1 2025Date5/12/2025TimeBefore Market OpensConference Call DateN/AConference Call TimeN/AUpcoming EarningsMoonLake Immunotherapeutics' Q2 2026 earnings is estimated for Tuesday, August 4, 2026, based on past reporting schedules, with a conference call scheduled on Wednesday, August 5, 2026 at 12:30 PM ET. Check back for transcripts, audio, and key financial metrics as they become available.Conference Call ResourcesQuarterly Report (10-Q)Earnings HistoryCompany ProfilePowered by Earnings DocumentsQuarterly report(10-Q) MoonLake Immunotherapeutics Earnings HeadlinesEquities Analysts Offer Predictions for MLTX Q2 EarningsJuly 24, 2026 | americanbankingnews.comHC Wainwright Reaffirms Buy Rating for MoonLake Immunotherapeutics (NASDAQ:MLTX)July 22, 2026 | americanbankingnews.com3 Signs of The Biggest “Melt-Up” in U.S. HistoryIn 1995, a convergence of three economic triggers fueled the biggest market melt-up in U.S. history. One self-made investor, who grew up with little to his name, built an eight-figure fortune by recognizing the pattern early. Now this 30-plus year Wall Street veteran says those same three triggers appear to be converging again, and the next Fed meeting under Chairman Warsh could confirm it. He believes this setup could send one corner of the market sharply higher once more.July 28 at 1:00 AM | True Market Insiders (Ad)Moonlake Immunotherapeutics Share Price (MLTX.US)July 15, 2026 | lse.co.ukSLS Vs MLTX: Retail Traders Race To Pick Merck’s Next Biotech Buyout As Keytruda’s $31.7B Patent Cliff NearsJuly 12, 2026 | finance.yahoo.comMoonLake Immunotherapeutics Class AJuly 11, 2026 | edition.cnn.comSee More MoonLake Immunotherapeutics Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like MoonLake Immunotherapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on MoonLake Immunotherapeutics and other key companies, straight to your email. Email Address About MoonLake ImmunotherapeuticsMoonLake Immunotherapeutics (NASDAQ:MLTX), a clinical-stage biopharmaceutical company, engages in developing therapies. It develops Sonelokimab, a novel investigational Nanobody for the treatment of inflammation diseases; and hidradenitis suppurativa, psoriatic arthritis, axial spondyloarthritis, and psoriasis. MoonLake Immunotherapeutics was incorporated in 2020 and is headquartered in Zug, Switzerland.View MoonLake Immunotherapeutics ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles These 3 Stocks Have Soared in 2026—Can They Keep Climbing?Hasbro’s Earnings Beat Shows Why This Is No Longer Just a Toy StoryRambus: Another AI Phoenix Ready to Rise From the Ashes of CorrectionAmkor Sells Off After Earnings—Why Weak Guidance Isn't the Real StoryWestern Digital’s Earnings Will Test Whether Its AI Rally Has More RoomIs the Market Mispricing ServiceNow's AI Future?Whirlpool’s Report May Show How Frozen the Housing Market Really Is Upcoming Earnings Agnico Eagle Mines (7/29/2026)General Dynamics (7/29/2026)L3Harris Technologies (7/29/2026)Automatic Data Processing (7/29/2026)Amphenol (7/29/2026)ARM (7/29/2026)Fortinet (7/29/2026)Lam Research (7/29/2026)Meta Platforms (7/29/2026)Microsoft (7/29/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
